Combat Disruption in Gene Therapy Development

Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined. How can sponsors keep pace with this rapidly growing market and avoid costly delays that can threaten critical timelines?

Selecting the appropriate genetic analysis methods can help biopharmaceutical companies avoid costly workflow disruptions and accelerate time to market.

This whitepaper highlights common challenges in gene therapy development and explores the latest analytical approaches available to combat workflow disruption.

Download this whitepaper to explore:

• The importance of standardization in gene therapy development 
• The benefits of genetic analysis tools for product manufacturing and controls (CMC) testing 
• Ways to optimize experimental reproducibility in your gene therapy development workflow